Pharmaceutical Executive
Witnessing an industry's wild ride is perhaps the best reason to work for a business magazine. You've given us 25 years of excitement. And we plan to pay you back.
Following an industry's wild ride is one of the great pleasures of being a trade journalist. From that perspective, I could hardly ask for a better subject matter than pharma. Here at Pharm Exec, we've been spending a lot of time thinking about the industry and its recent past, as we prepare for our year-long celebration of our 25th anniversary. (I don't want to spoil all the surprises just yet, but we think you'll enjoy and benefit from the events and editorial projects we have in the works.) As we look over the pharma-related events that have taken place since the magazine launched in January of 1981, it's hard not to be left gasping. Here's just a tiny sample:
Patrick Clinton
I could go on and on. The point is clear, though. This has been an amazing quarter century for pharma, and it has brought us to a point at which the next quarter century can only be more of the same. New markets will emerge in India, China, and Latin America. New techniques—especially nanotechnology and gene therapy—will come of age. The industry will weather the coming years of belt tightening and become something different and, one hopes, stronger. A lot of political football will be played, and who knows, at some point, maybe some other industry will replace pharma as ball.
It should be an exciting ride, not necessarily fun, but important not just for the industry but for patients as well. I know you're on board, and your friends here at Pharm Exec are as well. We've always tried to bring you the tools and ideas you need to survive and thrive on the roller coaster that is pharma. For our next 25 years, we promise to look harder, probe deeper, think more expansively, and bring you more value. Happy birthday from us.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.